Back to top
more

Vanda Pharmaceuticals (VNDA)

(Real Time Quote from BATS)

$4.20 USD

4.20
144,890

0.00 (0.00%)

Updated Aug 8, 2025 01:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (142 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Envision Healthcare Acquires Desert Mountain Consultants

by Zacks Equity Research

Envision Healthcare Corporation (EVHC), a provider of physician-led outsourced medical services to consumers, hospitals and healthcare systems in the U.S., recently announced the acquisition of Desert Mountain Consultants in Anesthesia, Inc.

    Zacks Equity Research

    Proteon Slips to 52-Week Low on Kidney Disease Study Data

    by Zacks Equity Research

    Proteon's (PRTO) shares hit a 52-week low after reporting poor top-line phase III data on vonapanitase in patients with chronic kidney disease.

      Zacks Equity Research

      Alexion Slips to 52-Week Low as CEO, CFO Quit amid Probe

      by Zacks Equity Research

      Alexion's (ALXN) shares plunged after the company's board of directors announced new leadership appointments.

        Zacks Equity Research

        Roche/AbbVie's Leukemia Drug Venclyxto Gains EU Approval

        by Zacks Equity Research

        Roche (RHHBY) and AbbVie's (ABBV) Venclyxto has gained EU approval for the treatment of appropriate patients with hard-to-treat chronic lymphocytic leukemia.

          Zacks Equity Research

          Corcept Korlym Positive in Phase I/II Breast Cancer Study

          by Zacks Equity Research

          Corcept Therapeutics (CORT) announced encouraging efficacy data from a phase I/II study on Korlym in patients with metastatic triple-negative breast cancer.

            Zacks Equity Research

            Horizon (HZNP) Stock Sinks, Friedreich's Ataxia Study Fails

            by Zacks Equity Research

            Horizon Pharma (HZNP) has decided to discontinue the development of Actimmune for Friedreich's ataxia after a phase III study failed to meet key endpoints.

              Zacks Equity Research

              AstraZeneca (AZN) Presents Tagrisso Data at Medical Meeting

              by Zacks Equity Research

              AstraZeneca plc (AZN) presented positive data from a randomized phase III study (AURA3) on its lung cancer drug Tagrisso at a lung cancer conference in Vienna, Austria.

                Zacks Equity Research

                Sage Therapeutics Stock Up on SAGE-547 Regulatory Update

                by Zacks Equity Research

                Sage (SAGE) announced expedited development plan on SAGE-547 following receipt of formal meeting minutes from a breakthrough therapy meeting with the FDA.

                  Zacks Equity Research

                  Theravance Stock Up on Fast Track Status for Velusetrag

                  by Zacks Equity Research

                  Theravance (TBPH) received Fast Track status from the FDA for velusetrag for idiopathic and diabetic gastroparesis.

                    Zacks Equity Research

                    Bristol-Myers Reports Data from Opdivo Combination Studies

                    by Zacks Equity Research

                    Bristol-Myers (BMY) presented multiple data from Opdivo combination studies.

                      Zacks Equity Research

                      GW Pharma (GWPH) Posts Narrower-than-Expected Q4 Loss

                      by Zacks Equity Research

                      GW Pharmaceuticals (GWPH) reported a narrower-than-expected loss of 89 cents per share in the fourth quarter of fiscal 2016 (ended Sep 30, 2016).

                        Zacks Equity Research

                        Novo Nordisk Files Regulatory Application for Semaglutide

                        by Zacks Equity Research

                        Novo Nordisk (NVO) submitted regulatory application for semaglutide in both the U.S. and the EU for the treatment of adults with type II diabetes.

                          Zacks Equity Research

                          Acceleron, Celgene Present Myelodysplastic Syndromes Data

                          by Zacks Equity Research

                          Acceleron (XLRN) and Celgene (CELG) announced updated data from the ongoing phase II studies on luspatercept in myelodysplastic syndromes patients.

                            Zacks Equity Research

                            Alnylam Reports Positive Data on Fitusiran, Givosiran

                            by Zacks Equity Research

                            Alnylam (ALNY) announced new positive data from an ongoing phase II OLE study on fitusiran for the treatment of patients with hemophilia A or B, without inhibitors.

                              Zacks Equity Research

                              Pfizer (PFE) Presents Favorable Data on Leukemia Candidate

                              by Zacks Equity Research

                              Pfizer Inc. (PFE) announced new positive data from a randomized phase II study on its investigational candidate glasdegib (PF-04449913) for the first-line treatment of patients with acute myeloid leukemia (AML).

                                Zacks Equity Research

                                Incyte Jakafi Positive in Pooled Analysis of Five-Year Data

                                by Zacks Equity Research

                                Incyte (INCY) announced pooled analysis of five-year data from two phase III studies on Jakafi, which support previous long-term results.

                                  Zacks Equity Research

                                  Alexion Presents Data from Ultra-Rare Blood Disorder Study

                                  by Zacks Equity Research

                                  Alexion Pharmaceuticals (ALXN) presented new data from a dose-escalation study on ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria at ASH.

                                    Zacks Equity Research

                                    Pfizer Offers Positive Phase III Data on Pediatric Epilesy Drug

                                    by Zacks Equity Research

                                    Pfizer Inc. (PFE) announced positive top-line results from a phase III study evaluating its marketed drug, Lyrica (pregabalin), as adjunctive therapy for the treatment of pediatric patients suffering from epilepsy with partial-onset seizures.

                                      Zacks Equity Research

                                      bluebird Stock Up on Positive Interim Multiple Myeloma Data

                                      by Zacks Equity Research

                                      bluebird bio (BLUE) reported encouraging interim phase I data on its anti-BCMA CAR T cell candidate, bb2121, in relapsed/refractory multiple myeloma patients.

                                        Zacks Equity Research

                                        Merck KGaA (MKGAF) Expands Distribution Deal with Roche

                                        by Zacks Equity Research

                                        Merck (MKGAF) announced that it has expanded the distribution alliance with Roche (RHHBY) to include enzyme products ??? PCR and qPCR.

                                          Zacks Equity Research

                                          Heat Biologics Stock Falls on Negative Bladder Cancer Data

                                          by Zacks Equity Research

                                          Heat Biologics (HTBX) presented disappointing top-line phase II data from the bladder cancer study on its lead pipeline candidate, HS-410.

                                            Zacks Equity Research

                                            AbbVie Crohn's Disease Drug Gets Orphan Drug Status in U.S.

                                            by Zacks Equity Research

                                            AbbVie Inc. (ABBV) announced that the FDA has granted Orphan Drug Designation to its investigational IL-23 inhibitor, risankizumab (ABBV-066; formerly BI 655066), for the treatment of Crohn's disease in pediatric patients.

                                              Zacks Equity Research

                                              Ultragenyx (RARE) Reports Positive Phase II Study on UX007

                                              by Zacks Equity Research

                                              Ultragenyx (RARE) announced positive data from a phase II study on UX007 for the treatment of patients with long-chain fatty acid oxidation disorder (LC-FAOD).

                                                Zacks Equity Research

                                                Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors

                                                by Zacks Equity Research

                                                Agenus (AGEN) announced that it has dosed the first patient in a phase I/II study on INCAGN1949 for the treatment of patients with solid tumors.

                                                  Zacks Equity Research

                                                  Cytori Scleroderma Study Two-Year Follow-Up Data Published

                                                  by Zacks Equity Research

                                                  Cytori Therapeutics (CYTX) announced the publication of two year follow-up data from the scleroderma study.